Cited by 369Liver Disease Diagnosis and TreatmentCholesterol and Lipid MetabolismCancer, Lipids, and Metabolism

The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.

Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH

Caballero, Francisco, Fernández, Anna, De Lacy, Antonio M., Fernández-Checa, Jose C., Caballería, Juan, García-Ruiz, Carmen·2009·Journal of Hepatology

DOI 10.1016/j.jhep.2008.12.016

Open this paper in CoChat — free account

Abstract

Background/aims Non-alcoholic fatty liver disease (NAFLD) pathogenesis remains unknown. Due to the emerging role of free cholesterol (FC) in NAFLD, our aim was to examine the correlation between FC accumulation in patients with NAFLD and the expression of enzymes that regulate cholesterol homeostasis. Methods Filipin staining, indicative of FC accumulation, and real-time PCR analyses were performed in 31 NAFLD patients and in seven controls. Results All NASH patients (n=14) and 4 out of 17 patients with steatosis exhibited filipin staining compared to controls (0 out of 7 subjects with normal liver histology and BMI). Sterol regulatory element-binding protein-2 (SREBP-2) mRNA levels were 7- and 3-fold higher in NASH and steatosis patients, respectively, compared to controls. Since hydroxymethylglutaryl-CoA (HMG-CoA) reductase is the key enzyme in cholesterol synthesis and transcriptionally controlled by SREBP-2 we measured its mRNA levels, being 3- to 4-fold higher in NAFLD compared to controls, without any difference between NASH and steatosis patients. Fatty acid synthase (FAS) and SREBP-1c expression were not significantly induced in NAFLD, while ATP-binding cassette sub-family G member 1 (ABCG1), a transporter involved in cholesterol egress, and acyl-CoA-cholesterol acyltransferase mRNA levels were modestly increased (1.5- to 2.5-fold, p<0.05), regardless of fibrosis. Interestingly, mRNA levels of steroidogenic acute regulatory protein (StAR), a mitochondrial-cholesterol transporting polypeptide, increased 7- and 15-fold in steatosis and NASH patients, respectively, compared to controls. Conclusions FC increases in NASH and correlates with SREBP-2 induction. Moreover, StAR overexpression in NASH suggests that mitochondrial FC may be a player in disease progression and a novel target for intervention.

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2008.12.016

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
Brown, M. S., & Goldstein, J. L. (1997) · Cell · doi:10.1016/s0092-8674(00)80213-5 · Cited by 3,834
Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Molecular mediators of hepatic steatosis and liver injury
Browning, J. D., & Horton, J. D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422422 · Cited by 1,772
Cellular cholesterol trafficking and compartmentalization
Ikonen, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2336 · Cited by 1,506

Show all 39 references

Sorted by citations

NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
Mridha, A. R., Wree, A., Robertson, A. A. B., Yeh, M. M., Johnson, C. D., Van Rooyen, D. M., Haczeyni, F., Teoh, N. C.-H., Savard, C., Ioannou, G. N., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.01.022 · Cited by 1,110
Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease
Lebeaupin, C., Vallée, D., Hazari, Y., Hetz, C. A., Chevet, É., & Bailly‐Maitre, B. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.06.008 · Cited by 971
Pathophysiology of diabetic dyslipidaemia: where are we?
Vergès, B. (2015) · Diabetologia · doi:10.1007/s00125-015-3525-8 · Cited by 708
Metabolic Activation of Intrahepatic CD8+ T Cells and NKT Cells Causes Nonalcoholic Steatohepatitis and Liver Cancer via Cross-Talk with Hepatocytes
Wolf, M. J., Adili, A., Piotrowitz, K., Abdullah, Z., Boege, Y., Stemmer, K., Ringelhan, M., Simonavicius, N., Egger, M., Wohlleber, D., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.003 · Cited by 678
Increased Hepatic Synthesis and Dysregulation of Cholesterol Metabolism Is Associated with the Severity of Nonalcoholic Fatty Liver Disease
Min, H., Kapoor, A., Fuchs, M. A., Mirshahi, F., Zhou, H., Maher, J. W., Kellum, J. M., Warnick, R., Contos, M. J., & Sanyal, A. J. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.004 · Cited by 668
Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease
Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016) · Metabolism · doi:10.1016/j.metabol.2016.02.014 · Cited by 570
A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer
Tsuchida, T., Lee, Y. A., Fujiwara, N., Ybanez, M., Allen, B., Martins, S., Fiel, M. I., Goossens, N., Chou, H.-I., Hoshida, Y., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.011 · Cited by 583
Glutathione and mitochondria
Ribas, V., García‐Ruiz, C., & Fernández-Checa, J. C. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00151 · Cited by 585
Self-citation
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
The Role of Cholesterol in the Pathogenesis of NASH
Ioannou, G. N. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.11.008 · Cited by 498
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH
Pierantonelli, I., & Svegliati‐Baroni, G. (2018) · Transplantation · doi:10.1097/tp.0000000000002480 · Cited by 473
Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis
Musso, G., Gambino, R., & Cassader, M. (2012) · Progress in Lipid Research · doi:10.1016/j.plipres.2012.11.002 · Cited by 415
Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal
Alkhouri, N., Dixon, L. J., & Feldstein, A. E. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.32 · Cited by 413
NASH is an Infl ammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications
Farrell, G. C., Rooyen, D. M. V., Gan, L. T., & Chitturi, S. (2012) · Gut and Liver · doi:10.5009/gnl.2012.6.2.149 · Cited by 408
Expression of miR-33 from an SREBP2 Intron Inhibits Cholesterol Export and Fatty Acid Oxidation*
Gerin, I., Clerbaux, L.-A., Haumont, O., Lanthier, N., Das, A. K., Burant, C. F., Leclercq, I. A., MacDougald, O. A., & Bommer, G. T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.152090 · Cited by 382
ER Stress Drives Lipogenesis and Steatohepatitis via Caspase-2 Activation of S1P
Kim, J. Y., Garcia-Carbonell, R., Yamachika, S., Zhao, P., Dhar, D., Loomba, R., Kaufman, R. J., Saltiel, A. R., & Karin, M. (2018) · Cell · doi:10.1016/j.cell.2018.08.020 · Cited by 333
Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic Steatohepatitis
Rooyen, D. M. V., Larter, C. Z., Haigh, W. G., Yeh, M. M., Ioannou, G. N., Kuver, R., Lee, S. P., Teoh, N., & Farrell, G. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.040 · Cited by 345
Nonobese fatty liver disease
Kim, D., & Kim, W. R. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.08.028 · Cited by 341
Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
Manne, V., Handa, P., & Kowdley, K. V. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.007 · Cited by 347
Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans
Pafili, K., & Roden, M. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101122 · Cited by 330
Targeting the alternative bile acid synthetic pathway for metabolic diseases
Jia, W. P., Wei, M., Rajani, C., & Zheng, X. (2020) · Protein & Cell · doi:10.1007/s13238-020-00804-9 · Cited by 330
Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl substances (PFAS) results in sex-dependent modulation of cholesterol metabolism and liver injury
Roth, K., Yang, Z., Agarwal, M., Liu, W. J., Peng, Z., Long, Z., Birbeck, J. A., Westrick, J. A., Liu, W., & Petriello, M. C. (2021) · Environment International · doi:10.1016/j.envint.2021.106843 · Cited by 322
Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
Argüello, G., Balboa, E., Arrese, M. A., & Zanlungo, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.05.015 · Cited by 320
Oxysterols in the pathogenesis of major chronic diseases
Poli, G., Biasi, F., & Leonarduzzi, G. (2013) · Redox Biology · doi:10.1016/j.redox.2012.12.001 · Cited by 311
Free radical biology for medicine: learning from nonalcoholic fatty liver disease
Serviddio, G., Bellanti, F., & Vendemiale, G. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.08.174 · Cited by 272
Macrophage MerTK Promotes Liver Fibrosis in Nonalcoholic Steatohepatitis
Cai, B., Dongiovanni, P., Corey, K. E., Wang, X., Shmarakov, I. O., Zheng, Z., Kasikara, C., Davra, V., Meroni, M., Chung, R. T., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.013 · Cited by 266
Cellular Mechanisms of Liver Fibrosis
Acharya, P., Chouhan, K., Weiskirchen, S., & Weiskirchen, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.671640 · Cited by 252
Specific Contribution of Methionine and Choline in Nutritional Nonalcoholic Steatohepatitis
Caballero, F., Fernández, A., Matías, N., Martínez-Gili, L., Fucho, R., Elena, M., Caballería, J., Morales, A., Fernández-Checa, J. C., & García‐Ruiz, C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.099333 · Cited by 245
Self-citation
Danger-Associated Molecular Patterns (DAMPs): Molecular Triggers for Sterile Inflammation in the Liver
Mihm, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103104 · Cited by 232
Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
Horn, C. L., Morales, A. L., Savard, C. E., Farrell, G. C., & Ioannou, G. N. (2021) · Hepatology Communications · doi:10.1002/hep4.1801 · Cited by 224
Cholesterol Stabilizes TAZ in Hepatocytes to Promote Experimental Non-alcoholic Steatohepatitis
Wang, X., Cai, B., Yang, X., Sonubi, O. O., Zheng, Z., Ramakrishnan, R., Shi, H., Valenti, L., Pajvani, U. B., Sandhu, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.03.010 · Cited by 204
Molecular Pathogenesis of NASH
Caligiuri, A., Gentilini, A., & Marra, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091575 · Cited by 219
Non-alcoholic fatty liver disease: What the clinician needs to know
Machado, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i36.12956 · Cited by 215
Redox Control of Liver Function in Health and Disease
Marí, M., Colell, A., Morales, A., von Montfort, C., García‐Ruiz, C., & Fernández-Checa, J. C. (2009) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.2634 · Cited by 203
Self-citation
Mechanisms of Lipotoxicity in NAFLD and Clinical Implications
Ibrahim, S. H., Kohli, R., & Gores, G. J. (2011) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e31822578db · Cited by 207
Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent
Gan, L. T., Rooyen, D. M. V., Koina, M. E., McCuskey, R. S., Teoh, N., & Farrell, G. C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.024 · Cited by 199
Mitochondrial Oxidative Stress and Antioxidants Balance in Fatty Liver Disease
García‐Ruiz, C., & Fernández-Checa, J. C. (2018) · Hepatology Communications · doi:10.1002/hep4.1271 · Cited by 202
Self-citation
Mitochondrial cholesterol: Metabolism and impact on redox biology and disease
Goicoechea, L., de la Rosa, L. C., Torres, S., García‐Ruiz, C., & Fernández-Checa, J. C. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102643 · Cited by 196
Self-citation
Pathogenesis of NASH: how metabolic complications of overnutrition favour lipotoxicity and pro-inflammatory fatty liver disease
Farrell, G. C., Haczeyni, F., & Chitturi, S. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-8684-7_3 · Cited by 178
Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis
Schierwagen, R., Maybüchen, L., Zimmer, S., Hittatiya, K., Bäck, C., Klein, S., Uschner, F., Reul, W., Boor, P., Nickenig, G., et al. (2015) · Scientific Reports · doi:10.1038/srep12931 · Cited by 176
New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
Méndez‐Sánchez, N., Cruz-Ramón, V., Ramírez-Pérez, O., Hwang, J. P., Barranco-Fragoso, B., & Córdova‐Gallardo, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072034 · Cited by 177
Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective
Gusdon, A. M., Song, K., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 172
The mammalian START domain protein family in lipid transport in health and disease
Clark, B. J. (2011) · Journal of Endocrinology · doi:10.1530/joe-11-0313 · Cited by 174
Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis
Koh, E. H., Yoon, J. E., Ko, M. S., Leem, J., Yun, J.-Y., Hong, C. H., Cho, Y. K., Lee, S. E., Jang, J. E., Baek, J. Y., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322509 · Cited by 156
Self-citation
Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity
Simonen, P. P., Kotronen, A., Hallikainen, M., Sevastianova, K., Makkonen, J., Hakkarainen, A., Lundbom, N. M. I., Miettinen, T. A., Gylling, H. K., & Yki‐Järvinen, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.037 · Cited by 157
Redox Balance in the Pathogenesis of Nonalcoholic Fatty Liver Disease: Mechanisms and Therapeutic Opportunities
Gambino, R., Musso, G., & Cassader, M. (2010) · Antioxidants and Redox Signaling · doi:10.1089/ars.2009.3058 · Cited by 147
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR
Sun, C., Huang, F., LIU, X., Xiao, X., Yang, M., Hu, G. M., Liu, H., & Liao, L. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2076 · Cited by 147
Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease
Wang, J., He, W., Tsai, P.-J., Chen, P.-H., Ye, M., Guo, J., & Su, Z. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01210-0 · Cited by 158
Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD)
Syed‐Abdul, M. M. (2023) · Metabolites · doi:10.3390/metabo14010012 · Cited by 166
Lipidomics in non-alcoholic fatty liver disease
Kartsoli, S., Kostara, C. E., Tsimihodimos, V., Bairaktari, E. T., & Christodoulou, D. K. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i8.436 · Cited by 149
Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure
Torres, S., Baulies, A., Insausti-Urkia, N., Alarcón‐Vila, C., Fucho, R., Solsona‐Vilarrasa, E., Núñez, S., Robles, D., Ribas, V., Wakefield, L., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.04.023 · Cited by 138
Self-citation
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis
Bellanti, F., Villani, R., Facciorusso, A., Vendemiale, G., & Serviddio, G. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.023 · Cited by 136
Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids
de Castro, G. S., & Calder, P. C. (2017) · Clinical Nutrition · doi:10.1016/j.clnu.2017.01.006 · Cited by 137
Anti-steatotic and anti-inflammatory roles of syringic acid in high-fat diet-induced obese mice
Ham, J. R., Lee, H.-I., Choi, R., Sim, M., Seo, K., & Lee, M. (2016) · Food & Function · doi:10.1039/c5fo01329a · Cited by 131
Mitochondrial cholesterol: mechanisms of import and effects on mitochondrial function
Martin, L. A., Kennedy, B. E., & Karten, B. (2016) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-014-9592-6 · Cited by 128
The Role of Lipid and Lipoprotein Metabolism in Non‐Alcoholic Fatty Liver Disease
Perla, F. M., Prelati, M., Lavorato, M., Visicchio, D., & Anania, C. (2017) · Children · doi:10.3390/children4060046 · Cited by 144
Advanced preclinical models for evaluation of drug-induced liver injury – consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET]
Fernández-Checa, J. C., Bagnaninchi, P., Ye, H., Sancho‐Bru, P., Falcón‐Pérez, J. M., Royo, F., García‐Ruiz, C., Konu, Ö., Miranda, J. P., Lunov, O., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.021 · Cited by 131
Self-citation
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome
Rooyen, D. M. V., Gan, L. T., Yeh, M. M., Haigh, W. G., Larter, C. Z., Ioannou, G. N., Teoh, N., & Farrell, G. C. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.024 · Cited by 125
Mitochondrial dysfunction in non-alcoholic fatty liver disease and insulin resistance: Cause or consequence?
García‐Ruiz, C., Baulies, A., Marí, M., García-Rovés, P. M., & Fernández-Checa, J. C. (2013) · Free Radical Research · doi:10.3109/10715762.2013.830717 · Cited by 119
Self-citation
Cholesterol and peroxidized cardiolipin in mitochondrial membrane properties, permeabilization and cell death
Montero, J., Marı́, M., Colell, A., Morales, A., Basáñez, G., García‐Ruiz, C., & Fernández-Checa, J. C. (2010) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2010.02.010 · Cited by 112
Self-citation
Activation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase during high fat diet feeding
Wu, N., Sarna, L. K., Hwang, S., Zhu, Q., Wang, P., Siow, Y. L., & Karmin, O. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.04.024 · Cited by 111
Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice
Wouters, K., van Bilsen, M., van Gorp, P. J., Bieghs, V., Lütjohann, D., Kerksiek, A., Staels, B., Hofker, M. H., & Shiri-Sverdlov, R. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.01.046 · Cited by 109
Cholesterol absorption decreases after Roux-en-Y gastric bypass but not after gastric banding
Pihlajamäki, J., Grönlund, S., Simonen, M., Käkelä, P., Moilanen, L., Pääkkönen, M. E., Pirinen, E., Kolehmainen, M., Kärjä, V. J., Kainulainen, S., et al. (2009) · Metabolism · doi:10.1016/j.metabol.2009.10.004 · Cited by 112
The LATS2 tumor suppressor inhibits SREBP and suppresses hepatic cholesterol accumulation
Aylon, Y., Gershoni, A., Rotkopf, R., Biton, I. E., Porat, Z., Koh, A. P., Sun, X., Lee, Y., Fiel, M.-I., Hoshida, Y., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)61580-0 · Cited by 105
Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity
Zhang, D., Tong, X., VanDommelen, K., Gupta, N., Stamper, K., Brady, G. F., Meng, Z., Lin, J. D., Rui, L., Omary, M. B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci89934 · Cited by 117
Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis
Zhao, L., Chen, Y., Tang, R., Chen, Y., Li, Q., Gong, J., Huang, A., Varghese, Z., Moorhead, J. F., & Ruan, X. Z. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06560.x · Cited by 92
Non-alcoholic steatohepatitis: The role of oxidized low-density lipoproteins
Walenbergh, S. M. A., Koek, G. H., Bieghs, V., & Shiri‐Sverdlov, R. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.014 · Cited by 100
STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway
de la Rosa, L. C., García‐Ruiz, C., Vallejo, C., Baulies, A., Núñez, S., Monte, M. J., Marı́n, J. J. G., Baila-Rueda, L., Cenarro, A., Civeira, F., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.01.028 · Cited by 101
Self-citation
Genomic aspects of NAFLD pathogenesis
Naik, A., Košir, R., & Rozman, D. (2013) · Genomics · doi:10.1016/j.ygeno.2013.03.007 · Cited by 108
Prebiotic approach alleviates hepatic steatosis: Implication of fatty acid oxidative and cholesterol synthesis pathways
Pachikian, B. D., Essaghir, A., Demoulin, J., Catry, É., Neyrinck, A. M., Dewulf, E. M., Sohet, F. M., Portois, L., Clerbaux, L., Carpentier, Y., et al. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200364 · Cited by 99
An FGF15/19-TFEB regulatory loop controls hepatic cholesterol and bile acid homeostasis
Wang, Y., Gunewardena, S., Li, F., Matye, D. J., Chen, C., Chao, X., Jung, T., Zhang, Y., Czerwiński, M., Ni, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17363-6 · Cited by 100
Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment
Byrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 113
Nuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
Cholesterol homeostasis: Researching a dialogue between the brain and peripheral tissues
Gliozzi, M., Musolino, V., Bosco, F., Scicchitano, M., Scarano, F., Nucera, S., Zito, M. C., Ruga, S., Carresi, C., Macrì, R., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105215 · Cited by 96
The Effect of Artichoke Leaf Extract on Alanine Aminotransferase and Aspartate Aminotransferase in the Patients with Nonalcoholic Steatohepatitis
Rangboo, V., Noroozi, M., Zavoshy, R., Rezadoost, S. A., & Mohammadpoorasl, A. (2016) · International Journal of Hepatology · doi:10.1155/2016/4030476 · Cited by 93
Recent research trends and updates on nonalcoholic fatty liver disease
Yoo, J., Kim, W. K., Kim, M. Y., Jun, D. W., Kim, S. G., Yeon, J.-E., Lee, J. W., Cho, Y. K., Park, S. H., & Sohn, J. H. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0037 · Cited by 94
Effects of High-Fat Diet on Steatosis, Endoplasmic Reticulum Stress and Autophagy in Liver of Tilapia (Oreochromis niloticus)
Jia, R., Cao, L., Du, J., He, Q., Gu, Z., Jeney, G., Xu, P., & Yin, G. (2020) · Frontiers in Marine Science · doi:10.3389/fmars.2020.00363 · Cited by 93
Chronic Alcohol Consumption Disrupted Cholesterol Homeostasis in Rats: Down‐Regulation of Low‐Density Lipoprotein Receptor and Enhancement of Cholesterol Biosynthesis Pathway in the Liver
Wang, Z., Yao, T., & Song, Z. (2009) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2009.01111.x · Cited by 91
Lipoprotein subclass metabolism in nonalcoholic steatohepatitis
Männistö, V., Simonen, M., Soininen, P., Tiainen, M., Kangas, A. J., Kamińska, D., Venesmaa, S., Käkelä, P., Kärjä, V. J., Gylling, H., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.p054387 · Cited by 90
Hepatic iron loading in mice increases cholesterol biosynthesis†
Graham, R. M., Chua, A. C. G., Carter, K. W., Delima, R. D., Johnstone, D. M., Herbison, C. E., Firth, M. J., O’Leary, R., Milward, E. A., Olynyk, J. K., et al. (2010) · Hepatology · doi:10.1002/hep.23712 · Cited by 92
Testosterone Replacement Ameliorates Nonalcoholic Fatty Liver Disease in Castrated Male Rats
Nikolaenko, L., Jia, Y., Wang, C., Diaz‐Arjonilla, M., Yee, J. K., French, S. W., Liu, P. Y., Laurel, S., Chong, C., Lee, K., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1648 · Cited by 87
Protective role of endogenous plasmalogens against hepatic steatosis and steatohepatitis in mice
Jang, J. E., Park, H., Yoo, H. J., Baek, I., Yoon, J. E., Ko, M. S., Kim, A., Kim, H. S., Park, H., Lee, S. E., et al. (2017) · Hepatology · doi:10.1002/hep.29039 · Cited by 88
Self-citation
Endoplasmic reticulum stress related molecular mechanisms in nonalcoholic steatohepatitis
Bozaykut, P., Şahin, A., Karademir-Yilmaz, B., & Özer, N. K. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.07.001 · Cited by 88
Cholesterol Crystals in Hepatocyte Lipid Droplets Are Strongly Associated With Human Nonalcoholic Steatohepatitis
Ioannou, G. N., Landis, C. S., Jin, G., Haigh, W. G., Farrell, G. C., Kuver, R., Lee, S. P., & Savard, C. E. (2019) · Hepatology Communications · doi:10.1002/hep4.1348 · Cited by 84
Acid sphingomyelinase-ceramide system in steatohepatitis: A novel target regulating multiple pathways
García‐Ruiz, C., Mato, J. M., Vance, D., Kaplowitz, N., & Fernández-Checa, J. C. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.023 · Cited by 83
Self-citation
Traditional Chinese medicine in the treatment of nonalcoholic steatohepatitis
Chen, M., Xie, Y., Gong, S., Wang, Y., Yu, H., Zhou, T., Huang, F., Guo, X., Zhang, H., Huang, R., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105849 · Cited by 81
Hepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Chronic Administration of Proanthocyanidins or Docosahexaenoic Acid Reversess the Increase of miR-33a and miR-122 in Dyslipidemic Obese Rats
Baselga‐Escudero, L., Arola‐Arnal, A., Pascual‐Serrano, A., Ribas‐Latre, A., Casanova, E., Salvadó, M. J., Arola, L., & Bladé, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069817 · Cited by 79
Susceptibility of Different Mouse Wild Type Strains to Develop Diet-Induced NAFLD/AFLD-Associated Liver Disease
Fengler, V. H., Macheiner, T., Kessler, S. M., Czepukojc, B., Gemperlein, K., Müller, R., Kiemer, A. K., Magnes, C., Haybaeck, J., Lackner, C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155163 · Cited by 78
Hypoxic Signaling and Cholesterol Lipotoxicity in Fatty Liver Disease Progression
Tirosh, O. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2548154 · Cited by 77
LDLR inhibition promotes hepatocellular carcinoma proliferation and metastasis by elevating intracellular cholesterol synthesis through the MEK/ERK signaling pathway
Chen, Z., Chen, L., Sun, B., Liu, D., He, Y., Qi, L., Li, G., Han, Z., Zhan, L., Zhang, S., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101230 · Cited by 81
Histamine Regulation in Glucose and Lipid Metabolism via Histamine Receptors
Wang, K., Tanimoto, A., Yamada, S., Guo, X., Ding, Y., Watanabe, T., Watanabe, T., Kohno, K., Hirano, K., Tsukada, H., et al. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091198 · Cited by 83
Hepatic miR‐33a/miR‐144 and their target gene ABCA1 are associated with steatohepatitis in morbidly obese subjects
Vega‐Badillo, J., Gutiérrez‐Vidal, R., Hernández‐Pérez, H. A., Villamil‐Ramírez, H., León‐Mimila, P., Sánchez‐Muñoz, F., Morán‐Ramos, S., Larrieta‐Carrasco, E., Fernández‐Silva, I., Méndez‐Sánchez, N., et al. (2016) · Liver International · doi:10.1111/liv.13109 · Cited by 75
Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling
Zheng, Q., Martin, R. C. G., Shi, X., Pandit, H., Yu, Y., Liu, X., Guo, W., Tan, M., Bai, O., Meng, X., et al. (2020) · Theranostics · doi:10.7150/thno.45988 · Cited by 73
Molecular Interactions between NAFLD and Xenobiotic Metabolism
Naik, A., Belič, A., Zanger, U. M., & Rozman, D. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00002 · Cited by 79
Hepatic Macrophage as a Key Player in Fatty Liver Disease
Xu, L., Liu, W., Bai, F., Xu, Y., Liang, X., Ma, C., & Gao, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708978 · Cited by 73
Sterol Regulatory Element-Binding Factor 2 (SREBF-2) Predicts 7-Year NAFLD Incidence and Severity of Liver Disease and Lipoprotein and Glucose Dysmetabolism
Musso, G., Cassader, M., Bo, S., Michieli, F. D., & Gambino, R. (2012) · Diabetes · doi:10.2337/db12-0858 · Cited by 70
Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice
Wang, C., Yuan, R.-S., Zhuang, W., Sun, J., Wu, J., Li, H., & Chen, J. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0358-5 · Cited by 69
The future of liver transplantation
Feng, S., Roll, G. R., Rouhani, F. J., & Fueyo, A. S. (2024) · Hepatology · doi:10.1097/hep.0000000000000873 · Cited by 69
Nonalcoholic Fatty Liver Disease
Paredes, A. H., Torres, D. M., & Harrison, S. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.005 · Cited by 72

Authors: Caballero, F., Fernández, A., De Lacy, A. M., Fernández-Checa, J. C., Caballería, J., & García-Ruiz, C.
Affiliations: Consejo Superior de Investigaciones Científicas (ES)
ORCID: Caballería, Juan
Venue: Journal of Hepatology
Publisher: Elsevier BV
Published: 2009-04
Volume: 50
Issue: 4
Pages: 789-796
ISSN: 0168-8278 (ISSN-L)
DOI: 10.1016/j.jhep.2008.12.016
OpenAlex: W2010101404
Cited by: 368
References: 39
Citations by year: 2026: 9 · 2025: 21 · 2024: 25 · 2023: 26 · 2022: 18 · 2021: 24 · 2020: 28 · 2019: 18 · 2018: 27 · 2017: 24 · 2016: 30 · 2015: 20 · 2014: 21 · 2013: 22 · 2012: 15
FWCI: 12.37
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Journal of Hepatology (publishedVersion)
PubMed (publishedVersion)
DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders: National Institute on Alcohol Abuse and Alcoholism (P50-AA11999, P50AA011999)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, free cholesterol, SREBP2, steroidogenic acute regulatory protein, cholesterol homeostasis, HMG-CoA reductase, ABCG1, acyl-CoA:cholesterol acyltransferase, fatty acid synthase, SREBP-1c, mitochondrial cholesterol transport, steatosis, fibrosis
MeSH terms: ATP Binding Cassette Transporter, Subfamily G, Member 1, Steroidogenic Acute Regulatory Protein, Adult, Animals, Cholesterol, Fatty Liver, Female, Filipin, Humans, Hydroxymethylglutaryl CoA Reductases, Male, Middle Aged, Obesity, Morbid, Phosphoproteins, RNA, Messenger, DNA Primers, Mice, Knockout, ATP-Binding Cassette Transporters, Reverse Transcriptase Polymerase Chain Reaction, Diabetes Complications, Mice, Sterol Regulatory Element Binding Protein 1, Sterol Regulatory Element Binding Protein 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks